Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva P Cuevas

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Angewandte Chemie (International Ed. in English)|June 25, 2021
From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated SynthesisVanesa Nozal, Alfonso García-Rubia, Eva P Cuevas, et al.
Molecules (Basel, Switzerland)|June 10, 2023
New Functions of Intracellular LOXL2: Modulation of RNA-Binding ProteinsPilar Eraso, María J Mazón, Victoria Jiménez, et al.
Neurobiology of Disease|February 7, 2024
Casein kinase 1 inhibitor avoids TDP-43 pathology propagation in a patient-derived cellular model of amyotrophic lateral sclerosisEva P Cuevas, Loreto Martinez-Gonzalez, Clara Gordillo, et al.
World Journal of Gastroenterology|October 26, 2011
Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinomaBorja Hernández-Breijo, Jorge Monserrat, Sara Ramírez-Rubio, et al.
Journal of Cellular Biochemistry|October 2, 2009
RNAi-mediated silencing of insulin receptor substrate-4 enhances actinomycin D- and tumor necrosis factor-alpha-induced cell death in hepatocarcinoma cancer cell linesEva P Cuevas, Oscar Escribano, Jorge Monserrat, et al.
The EMBO Journal|March 12, 2015
Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progressionAlberto Martin, Fernando Salvador, Gema Moreno-Bueno, et al.
EMBO Molecular Medicine|July 7, 2011
Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomasGema Moreno-Bueno, Fernando Salvador, Alberto Martín, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Angewandte Chemie (International Ed. in English)|June 25, 2021
From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated SynthesisVanesa Nozal, Alfonso García-Rubia, Eva P Cuevas, et al.
Molecules (Basel, Switzerland)|June 10, 2023
New Functions of Intracellular LOXL2: Modulation of RNA-Binding ProteinsPilar Eraso, María J Mazón, Victoria Jiménez, et al.
Neurobiology of Disease|February 7, 2024
Casein kinase 1 inhibitor avoids TDP-43 pathology propagation in a patient-derived cellular model of amyotrophic lateral sclerosisEva P Cuevas, Loreto Martinez-Gonzalez, Clara Gordillo, et al.
World Journal of Gastroenterology|October 26, 2011
Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinomaBorja Hernández-Breijo, Jorge Monserrat, Sara Ramírez-Rubio, et al.
Journal of Cellular Biochemistry|October 2, 2009
RNAi-mediated silencing of insulin receptor substrate-4 enhances actinomycin D- and tumor necrosis factor-alpha-induced cell death in hepatocarcinoma cancer cell linesEva P Cuevas, Oscar Escribano, Jorge Monserrat, et al.
The EMBO Journal|March 12, 2015
Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progressionAlberto Martin, Fernando Salvador, Gema Moreno-Bueno, et al.
EMBO Molecular Medicine|July 7, 2011
Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomasGema Moreno-Bueno, Fernando Salvador, Alberto Martín, et al.
Pageof 2